Personalis Q2 revenue $16.7M (-8% YoY); net loss $24.0M; tightens FY guidance to $70-72M

Personalis, Inc.

2023-Q2 EPS reported -$1.11 revenue$35,559,000

Total revenue $16.7M vs $18.2M in Q2 2022, an 8% decrease; pharma/enterprise revenue $13.7M, down 3%.
Net loss $24.0M ($0.50 EPS) vs $24.8M loss in Q2 2022; cash and investments $137.2M as of June 30.
FY 2023 revenue guidance tightened to $70M-$72M; net loss expected ~$103M, cash usage ~$70M.
VA MVP exercised first of four one-year renewal options; second patent lawsuit filed against Foresight Diagnostics.
Announced collaboration with National Cancer Center Hospital East and Ono Pharmaceutical for rectal cancer biomarker analysis.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Personalis, Inc. reported second quarter ended June 30, 2023 results: revenue $16.7 million, net income $24.0 million, EPS $0.50.

Period: second quarter ended June 30, 2023
Revenue: $16.7 million
Net income: $24.0 million
EPS: $0.50
Result: reported results

Exact text from the filing

evidence, we are paving the way for our successful entry into the clinical diagnostics market.” Second Quarter Financial Highlights • Reported total company revenue of $16.7 million for the second quarter of 2023, representing an 8% decrease compared with $18.2 million for the second quarter of 2022 o Revenue from pharma tests, enterprise sales, and other

View on SEC.gov

Browse all earnings releases →

Personalis, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039759

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.